https://www.selleckchem.com/pr....oducts/zidesamtinib.
32 95% CI -1.86 to -0.78). Considering results in a systematic manner, AV accelerated tissue epithelialization and wound-healing process (N=3), reduced oral mucositis (N=3), and improved quality of life (N=1). AV might have beneficial effects in reducing pain scores and the severity of mucocutaneous problems compared with placebo, especially with limited mild to moderate adverse effects. AV may be used as an alternative and integrative approach to reducing symptom severity in mucocutaneous problems and the wound-healing process. Hi
Like
Comment
Share
